Ticker

Trinity Biotech (NASDAQ: TRIB - Get Free Report) is expected to release its Q4 2025 resultson Wednesday, April 8th. Analysts expect Trinity Biotech to post earnings of ($0.32) per share and revenue of $15.00 million for the quarter. Investors are encouraged to explore the company's upcoming Q4 2025 earning overview page for the latest details on

DUBLIN and NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a global diagnostics company, today announced successful results from a clinical study of a new, enhanced version of its EpiCapture™ prostate cancer test, engineered to deliver higher precision risk prediction of aggressive prostate cancer.

Trinity Biotech (NASDAQ: TRIB - Get Free Report) and CompuMed (OTCMKTS:CMPD - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk. Earnings and Valuation This table compares Trinity Biotech and

DUBLIN and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into a collaboration agreement with the University at Buffalo, New York (“UB”). The partnership focuses on advancing and commercializing a suite of proprietary…

Company begins roll out of innovative diabetes care HbA1c column system in Brazil  Commercial leadership strengthened with key appointment DUBLIN, March 12, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has commenced the commercial rollout in…